Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms 镥[177Lu]PSMA-0057 |
Target |
Mechanism PSMA modulators(Prostate-specific membrane antigen modulators), Ionising radiation emitters |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Prostatic Adenocarcinoma | Phase 1 | CN | 01 Mar 2023 | |
PSMA-Positive Prostatic Cancer | IND Approval | CN | 13 Oct 2024 |